PROJECT EVALUATION : Antikor
Hello everyone,
How many times have I wished to live multiple lives and see what would have happened if I had chosen this or that path? What would have happened if I had chosen to do a PhD in nutrigenomics, plants or cancer rather than in the degradation of proteins? While through the PhD, I got to know a lot about a little, here at Capital Cell, I get to know a little about a lot and I am fulfilling my curiosity thanks to all the amazing proposals that we receive.
Today I had the chance to witness (by means of this pitch deck) the evolution of cancer therapeutics. The English company Antikor is designing drugs -Fragment Drug Conjugates- to kill specific cells, only the cancerous ones.
I kindly ask you to review this proposal and share your opinion with me through the questionnaire.
With best wishes,
Pilar Puig Sàrries
PROJECT EVALUATION : Antikor
